This site is intended only for healthcare professionals resident in the Republic of Ireland
Meningococcal disease refers to any illness caused by the bacterium Neisseria meningitidis.1 There are six common serogroups of bacteria that cause most meningococcal disease worldwide - A, B, C, W, X and Y.2 The primary mode of transmission of Neisseria meningitidis is through respiratory droplet spread or by direct contact with respiratory secretions.2
Based on structural differences of the polysaccharide capsule, bacteria are classified into serogroups.1 Neisseria meningitidis uses the polysaccharide capsule to evade destruction by the immune system, using a protective shell to prevent binding of the complement system that could otherwise initiate lysis and phagocytosis. The complement-bacterium complex is called the C3b.3 Evasion can be enhanced by other methods including mimicry of host molecules, recruiting factor H and its genetic diversity.3
Figure 1: Polysaccharide capsule mechanism. Adapted from Tan LKK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med. 2010; 362:1511-20.
Meningococcal disease has an incubation period of typically 3 to 4 days, with a range of 1 to 10 days2
Invasive meningococcal disease (IMD) is a major cause of meningitis and septicaemia.1 Common symptoms of meningococcal meningitis include fever, headache, neck stiffness, altered mental status, nausea, vomiting and photophobia.1 Meningococcal sepsis symptoms typically include fever, a petechial or purpuric rash, septic shock, disseminated intravascular coagulation and multiple organ failure.1
In 1906, scientists began to recommend anti-meningococcal serum therapy to protect humans against meningococcal disease; a therapy based on antibodies initially derived from the blood of horses, and later from patients, or individuals recovering from meningococcal disease.4 Antibiotics revolutionised treatment for meningitis; however, they do not always act fast enough to prevent damage that the bacteria can cause. Ireland introduced a vaccine against meningococcal C disease (MenC vaccine) in 2000, meningococcal B disease (MenB vaccine) in 2016 and meningococcal ACWY disease (MenACWY vaccine) in 2019.5,6
Meningococcal vaccines help to protect against different serogroups of Neisseria meningitidis.7
Clinical suspicion of haemophilia should be raised for patients with a history of easy bruising, spontaneous, or excessive bleeding following trauma or surgery.1
Haemophilia management involves treating specific haemorrhages, as well as preventing bleed recurrence, limiting complications, and restoring tissue and/or organ function to a pre-bleed state.1
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023